{"brief_title": "Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma", "brief_summary": "This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.", "condition": "Pancreatic Cancer", "intervention_type": "Biological", "intervention_name": "G17DT Immunogen", "arm_group_label": "A", "criteria": "Inclusion criteria: - Clinical diagnosis of pancreatic adenocarcinoma and unsuitable for pancreatic tumor resection - Life expectancy of at least 3 months - Functional status by Karnofsky Index of at least 70 Exclusion criteria: - Prior treatment with chemotherapy, radiotherapy, or anti-cancer immunotherapy - Chronic use of corticosteroids, except for inhaled corticosteroids used for asthma or chronic obstructive pulmonary disease - Immunodeficiency - Bone marrow transplant within past year - Brain metastasis", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00044031.xml"}